{
  "id": "5c73ad087c78d69471000091",
  "type": "list",
  "question": "Which drugs are included in the Orkambi pill?",
  "ideal_answer": "Orkambi pill includes lumacaftor combined with ivacaftor. It is approved for treatment of cystic fibrosis with F508del-CFTR mutation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28667089",
    "http://www.ncbi.nlm.nih.gov/pubmed/28891346",
    "http://www.ncbi.nlm.nih.gov/pubmed/27792891",
    "http://www.ncbi.nlm.nih.gov/pubmed/29351449",
    "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
    "http://www.ncbi.nlm.nih.gov/pubmed/27990075",
    "http://www.ncbi.nlm.nih.gov/pubmed/29903751",
    "http://www.ncbi.nlm.nih.gov/pubmed/29146575",
    "http://www.ncbi.nlm.nih.gov/pubmed/27804127",
    "http://www.ncbi.nlm.nih.gov/pubmed/28611092",
    "http://www.ncbi.nlm.nih.gov/pubmed/28769592"
  ],
  "snippets": [
    {
      "text": "Thus studies were conducted to examine the effects of lumacaftor alone and lumacaftor in combination with ivacaftor (i.e., ORKAMBI) on the ability of human CF ( del508Phe/ del508Phe) monocyte-derived macrophages (MDMs) to phagocytose and kill Pseudomonas aeruginosa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29146575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In recent years, two modulators, ivacaftor (Kalydeco) and lumacaftor/ivacaftor (Orkambi), have been approved by the U.S. Food and Drug Administration to treat CF patients with certain CFTR mutations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29351449",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, ORKAMBI, a combination therapy that includes a corrector of the processing defect of F508del-CFTR (lumacaftor or VX-809) and a potentiator of channel activity (ivacaftor or VX-770), was approved for CF patients homozygous for this mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29903751",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In July 2015, the US Food and Drug Administration approved Orkambi (lumacaftor/ivacaftor), a combination drug that works on reversing the effects of the defective cystic fibrosis transmembrane conductance regulator protein. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28769592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: In 2016, the Food and Drug Administration and the European Commission approved LUM/IVA (Orkambi), a CFTR modulator that includes both a CFTR corrector and potentiator, for CF patients homozygous for the F508del CFTR mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28891346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination therapy of lumacaftor and ivacaftor (Orkambi\u00ae) is approved for patients bearing the major cystic fibrosis (CF) mutation: \u0394F508 It has been predicted that Orkambi\u00ae could treat patients with rarer mutations of similar \"theratype\"; however, a standardized approach confirming efficacy in these cohorts has not been reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28667089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ORKAMBI (ivacaftor-lumacaftor [LUMA]) and KALYDECO (ivacaftor; IVA) are two new breakthrough cystic fibrosis (CF) drugs that directly modulate the activity and trafficking of the defective CFTR underlying the CF disease state.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27792891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611092",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lisinopril oral solution (Qbrelis) for the treatment of hypertension, heart failure, and acute myocardial infarction; etanercept-szzs (Erelzi) for multiple autoimmune disorders; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27990075",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development.Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611092",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.ORKAMBI (ivacaftor-lumacaftor [LUMA]) and KALYDECO (ivacaftor; IVA) are two new breakthrough cystic fibrosis (CF) drugs that directly modulate the activity and trafficking of the defective CFTR underlying the CF disease state. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27792891",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In July 2015, the US Food and Drug Administration approved Orkambi (lumacaftor/ivacaftor), a combination drug that works on reversing the effects of the defective cystic fibrosis transmembrane conductance regulator protein. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28769592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination therapy of lumacaftor and ivacaftor (Orkambi\u00ae) is approved for patients bearing the major cystic fibrosis (CF) mutation: \u0394F508 It has been predicted that Orkambi\u00ae could treat patients with rarer mutations of similar theratype; however, a standardized approach confirming efficacy in these cohorts has not been reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28667089",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "lumacaftor, ivacaftor"
}